Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD (NCT06110130)
Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Non-Diabetic Chronic Kidney Disease
🩺 Plain-English Summary (8th-Grade Level)
Primary Objective: To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease (NDKD), on empagliflozin therapy. Primary Endpoint: We will assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein. Secondary Objectives: 1. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. 2. Correlate systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12) , hs-CRP and arterial stiffness measures with urine exosome-based podocyte protein estimation \[11, 27-29\]. 3. Correlate urine podocyte-specific protein markers with APOL1 mRNA expression levels in blood mononuclear cells (MNC)
Who can join: Review the eligibility criteria below.
Location: Washington DC Veterans Affairs Medical Center (688) — Washington D.C., District of Columbia
Age range: 19 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Washington DC Veterans Affairs Medical Center (688) — Washington D.C., District of Columbia
📞 Contact the Study Coordinator
Phone: (202) 745-8000
Email: sabyasachi.sen@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Kidney Diseases
- Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease — Port Jefferson Station, New York
- Combination of Novel Therapies for CKD Comorbid Depression — Stony Brook, New York
- Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) — Winnipeg, Manitoba
- Developing Tools for Dialysis Decision Support — Palo Alto, California
- BRINK (BRain In Kidney Disease) Memory Study 2.0 — Minneapolis, Minnesota
- Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Chicago, Illinois
Explore by condition: All Chronic Kidney Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.